Page last updated: 2024-12-07

rb 101

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RB 101: structure given in first source; inhibits enkephalinase and aminopeptidases; biologically cleaved at disulfide to produce inhibitors of both aminopeptidase N and neutral endopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119600
SCHEMBL ID18131934
MeSH IDM0199955

Synonyms (15)

Synonym
135949-60-9
rb-101
rb101
l-phenylalanine, n-(2-(((2-amino-4-(methylthio)butyl)dithio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester
n-(2-benzyl-3-((2-amino-4-methylthio)butyl dithio)-1-oxopropyl)phenylalanine benzyl ester
rb 101
benzyl (2s)-2-[[2-[[[(2s)-2-amino-4-methylsulfanylbutyl]disulfanyl]methyl]-3-phenylpropanoyl]amino]-3-phenylpropanoate
unii-qn6uq885qe
qn6uq885qe ,
SCHEMBL18131934
n-[2-[[[(2s)-2-amino-4-(methylthio)butyl]dithio]methyl]-1-oxo-3-phenylpropyl]-l-phenylalanine phenylmethyl ester
DTXSID60929187
Q7275904
l-phenylalanine, n-(2-((((2s)-2-amino-4-(methylthio)butyl)dithio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester
AKOS040747358

Research Excerpts

Overview

RB 101 is a recently reported systemically active mixed inhibitor prodrug of the two enzymes which metabolize the enkephalins neutral endopeptidase 24.11 and aminopeptidsase N.

ExcerptReferenceRelevance
"RB 101 is a recently reported systemically active mixed inhibitor prodrug of the two enzymes which metabolize the enkephalins neutral endopeptidase 24.11 and aminopeptidase N."( Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
Baamonde, A; Daugé, V; Fournié-Zaluski, MC; Fulga, IG; Roques, BP; Ruiz-Gayo, M; Turcaud, S, 1992
)
1.23

Effects

RB 101 has a promising potential role in the management of the opiate withdrawal syndrome. It could represent a promising alternative in the treatment of depressive patients who are unresponsive to, or intolerant of, classical antidepressants.

ExcerptReferenceRelevance
"4. RB 101 has a promising potential role in the management of the opiate withdrawal syndrome."( Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O, 1995
)
1.05
"4. RB 101 has a promising potential role in the management of the opiate withdrawal syndrome."( Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O, 1995
)
1.05
"As RB 101 has been reported to be almost devoid of opiate-related side-effects, it could represent a promising alternative in the treatment of depressive patients who are unresponsive to, or intolerant of, classical antidepressants."( Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.
Gilbert-Rahola, J; Maldonado, R; Micó, JA; Roques, BP; Smadja, C; Tejedor-Real, P, 1998
)
0.81

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for RB 101 was shifted to the left and the duration of reflex depression was significantly prolonged."( CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Elfvin, A; Fournié-Zaluski, MC; Hao, JX; Roques, BP; Wiesenfeld-Hallin, Z; Xu, XJ, 1997
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's34 (61.82)18.2507
2000's19 (34.55)29.6817
2010's1 (1.82)24.3611
2020's1 (1.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.45 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index47.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.51%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (96.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]